Counterfeit weight-loss pens pose severe health risks

Health authorities are raising alarms over the illegal market for weight-loss pens, which are widely used to treat obesity and diabetes. The circulation of counterfeit medications from unknown sources poses severe health risks, as these products may contain incorrect dosages, unknown substances, or harmful ingredients.

The World Health Organization (WHO) previously issued an alert regarding three falsified batches of semaglutide-based medication found in Brazil, the United Kingdom, and the United States.

In Brazil, regulatory actions have intensified. Between January and April 2026, Anvisa reported the seizure of over 1.3 million irregular injectable units and the closure of eight establishments. A joint operation with the Federal Police in April identified R$ 4.8 million in irregular transactions involving tirzepatide, with quantities sufficient to produce over one million injectable devices. Most recently, Anvisa prohibited the import, sale, and use of the T36 weight-loss pen.